Gene therapy injection for inherited corneal dystrophy
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a new gene therapy injection called GEB-101 for people with corneal dystrophy caused by a TGFBI gene change. The goal is to see if it is safe and can help improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed change (mutation) in the TGFBI gene.
- You have symptoms from your corneal dystrophy, like blurry vision or discomfort.
- You do not have other active eye problems (like infection or glaucoma) that could interfere.
- You have not had prior eye surgery in the study eye.
- You have not received gene therapy in either eye before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This trial tests a new gene therapy for Bietti's crystalline dystrophy, a rare inherited eye disease that causes progressive vision loss. The treatment aims to slow or stop vision loss by delivering a healthy gene to the eye.
This trial tests a simple cell treatment for a swollen cornea caused by cataract surgery. It aims to help your cornea become clear again without a full transplant.
This trial tests a new gene therapy called VG901, given as an injection into the eye, for people with retinitis pigmentosa caused by a specific genetic change in the CNGA1 gene. The goal is to see if it is safe and tolerable.
This trial tests an injection (PUMCH-E111) for people with a specific genetic form of inherited retinal dystrophy caused by RLBP1 mutations. It aims to see if the treatment is safe and can help preserve vision.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
Hear when a new Hereditary Corneal Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.